Drug intelligence / Profile preview

MEDiC-02

Development stage: Preclinical
Lead developer: Medic Life Sciences

Overview

MEDiC-02 is an early-stage therapeutic candidate currently in the preclinical discovery phase for the treatment of hepatocellular carcinoma (HCC). Developed by Medic Life Sciences, the program leverages the company's proprietary MC-3D platform, which combines 3D tumor models with CRISPR-based functional genomics to identify and validate novel cancer targets. As of the most recent pipeline disclosures, the specific molecular target and therapeutic modality (such as a small molecule or monoclonal antibody) for MEDiC-02 have not been publicly revealed.

Beyond the preview

Go deeper on MEDiC-02.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MEDiC-02.

Explore the full profile